News

Featured

Sharing Data to Improve Lives: The SRUK Patient Registry Survey

SRUK is developing a Patient Registry, with the aim of improving outcomes for people diagnosed with Scleroderma or Raynaud's. Our Registry will be a secure, anonymous database, containing health information about people living with the conditions. It will be used to improve our understanding of Scleroderma and Raynaud's and how different people are affected over time, to help accelerate research into new and better treatments designed to improve quality of life. Read on to find out what we learned through the SRUK Patient Registry Survey, and how it will help shape our Patient Registry.

Featured

SRUK's response to the Autumn Statement

SRUK asks the Chancellor to consider the impact of changes to disability benefits on people with scleroderma and we renew our call for more support with energy bills for those that need it most.

Featured

Government must expand Cost of Living Payments to protect health of those living with Raynaud's Phenomenon

Ahead of the Chancellor's Autumn Statement we are calling on the government to expand its Cost of Living Payment criteria to include people living with Raynaud’s Phenomenon.

Tuesday 19th April 2016

Largest scleroderma study to date has created a complete genetic map of the disease

Read Article

Friday 15th April 2016

How I Manage My Auto Immune Diseases Without Medication

Well! It’s not easy but I have managed it with a few changes over the years to my nutrition and a good exercise plan.

Read Article

Thursday 14th April 2016

What Exactly is 'Pre-Scleroderma'?

Read Article

Tuesday 12th April 2016

Endothelin-1 Receptor Blockers Again Shown to Be Ineffective in Treating Skin Fibrosis

Read Article

Saturday 2nd April 2016

What is research doing for me?

Prof. Denton, Consultant Rheumatologist at the Royal Free Hospital, London opened the World Systemic Sclerosis Congress with a presentation on 'What is research doing for me?' This uplifting and informative presentation highlighted the positive breakthroughs taking place in scleroderma research.

Read Article

Wednesday 30th March 2016

Halfway Point Marked in Scleroderma Patient Enrolment for Cytori's ECCS-50 Phase 3 Trial

Cytori Therapeutics has enrolled and treated its 40th patient with scleroderma in the Phase 3 STAR clinical trial for ECCS-50, marking 50 percent of target enrollment.

Read Article